{"doi":"10.1039/d0dt02152k","title":"Controllable synthesis of rare earth (Gd <sup>3+</sup> ,Tm <sup>3+</sup> ) doped Prussian blue for multimode imaging guided synergistic treatment","abstract":"Gd3+ and Tm3+ doped Prussian blue (Gd/Tm-PB) with high uniformity and dispersibility was synthesized by a facile solvothermal method. The conditions for the synthesis of Gd/Tm-PB were explored. Through the regulation of the ratio of Gd3+/Tm3+, the Gd/Tm-PB particles with the optimal size (about 150-200 nm) and the best fluorescence and photothermal effect were obtained. On the basis of the optimal Gd/Tm-PB, further coated by polydopamine (PDA) functionalized metal-organic frameworks (MOFs), a multifunctional platform Gd/Tm-PB@ZIF-8/PDA for cancer diagnosis and treatment was established. Doxorubicin (DOX) was selected as a drug model and the drug loading of Gd/Tm-PB@ZIF-8/PDA was found to be 81 mg g-1. Cytotoxicity analysis indicated that Gd/Tm-PB@ZIF-8/PDA was highly biocompatible. The DOX release at different pH values and GSH concentrations revealed an excellent pH/GSH-triggered drug release. Through the combination of the near infrared photothermal performance of Gd/Tm-PB, chemo-photothermal therapy can be achieved to further improve the anti-cancer efficiency. In addition, the Gd/Tm-PB@ZIF-8/PDA nanoparticles can be tracked by fluorescence imaging (FOI) and magnetic resonance imaging (MRI). Cell FOI and in vivo MRI experiments showed the potential application of Gd/Tm-PB@ZIF-8/PDA in dual mode imaging guided therapy. In vivo antitumor experiments demonstrated the higher anticancer efficacy of Gd/Tm-PB@ZIF-8/PDA with a combined effect of chemo-photothermal therapy. This work provides a new strategy for nano-drug carriers in the direction of integrated diagnosis and treatment.","journal":"Dalton Transactions","year":2020,"id":100887,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":28,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9468,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":495030,"name":"Bin Chi","orcid":null,"position":1,"is_corresponding":false},{"id":494421,"name":"Zhiyuan Han","orcid":"0000-0001-6421-8605","position":2,"is_corresponding":false},{"id":494422,"name":"Yuting He","orcid":"0000-0001-8092-6134","position":3,"is_corresponding":false},{"id":494423,"name":"Feng Tian","orcid":"0000-0001-8747-3959","position":4,"is_corresponding":false},{"id":494424,"name":"Zushun Xu","orcid":"0000-0001-7314-170X","position":5,"is_corresponding":false},{"id":286025,"name":"Ling Li","orcid":"0000-0002-2046-3462","position":6,"is_corresponding":false},{"id":494425,"name":"Jing Wang","orcid":"0000-0002-1246-991X","position":7,"is_corresponding":false},{"id":494420,"name":"Mingyue Xu","orcid":"0000-0002-0859-8794","position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":null,"created_at":"2026-07-18T22:39:01.863288Z","pmid":"32844843","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}